Cullinan Oncology/$CGEM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cullinan Oncology

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Ticker

$CGEM
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

111
Website
cullinantherapeutics.com

CGEM Metrics

BasicAdvanced
$459M
-
-$3.10
-0.07
-

What the Analysts think about CGEM

Analyst ratings (Buy, Hold, Sell) for Cullinan Oncology stock.

Bulls say / Bears say

Cullinan Therapeutics' strategic pivot to autoimmune diseases, particularly with CLN-978 targeting systemic lupus erythematosus, positions the company in a growing market with significant unmet needs. (biopharmadive.com)
The successful $280 million private placement enhances Cullinan's financial stability, extending its cash runway into 2028 and supporting ongoing development programs. (benzinga.com)
Positive Phase 2b REZILIENT1 trial results for zipalertinib in non-small cell lung cancer patients, showing a 40% objective response rate, demonstrate the potential of Cullinan's oncology pipeline. (investing.com)
The discontinuation of the B cell non-Hodgkin lymphoma study to focus on autoimmune indications may raise concerns about the company's commitment to its oncology pipeline. (fiercebiotech.com)
Morgan Stanley's reduction of Cullinan's price target to $38, citing disappointing results, reflects potential challenges in meeting market expectations. (investing.com)
The company's net loss increased to $48.5 million in Q1 2025 from $37.1 million in Q1 2024, indicating rising operational expenses that could impact financial sustainability. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

CGEM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CGEM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CGEM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs